Ku80 is highly expressed in lung adenocarcinoma and promotes cisplatin resistance

Journal of Experimental and Clinical Cancer Research

Volumn 31, Issue 1, 2012, Pages

  Ma, Qingshan ^a,b   Li, Ping ^a   Xu, Minyu ^a   Yin, Jinzhi ^a   Su, Zhenzhong ^a   Li, Wei ^a   Zhang, Jie ^a  

^a THE SECOND HOSPITAL OF JILIN UNIVERSITY   (China)

^b THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

Author keywords

Chemotherapy; Cisplatin; Ku80; Lung cancer; SiRNA

Indexed keywords

CASPASE 3; CISPLATIN; KU ANTIGEN; KU80 ANTIGEN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; CELL NUCLEUS ANTIGEN; DNA BINDING PROTEIN; PHARMACOLOGICAL BIOMARKER;

A-549 CELL LINE; A549/DDP CELL LINE; ADULT; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CHEMOSENSITIVITY; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; GENE KNOCKDOWN; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MTT ASSAY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ADENOCARCINOMA; DISEASE FREE SURVIVAL; DRUG EFFECT; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; LUNG TUMOR; METABOLISM; PATHOLOGY; PROGNOSIS; TUMOR CELL LINE;

ADENOCARCINOMA; ANTIGENS, NUCLEAR; APOPTOSIS; BIOMARKERS, PHARMACOLOGICAL; CASPASE 3; CELL LINE, TUMOR; CISPLATIN; DISEASE-FREE SURVIVAL; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; PROGNOSIS; RNA, SMALL INTERFERING;

EID: 84869885442     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-31-99     Document Type: Article

References (29)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
2. Fan Z, Schraeder R: The changing pathology of lung cancer. Surg Oncol Clin N Am 2011, 20:637-653.
3. Azzoli CG, Baker S, Temin S, Pao W, Aliff T, Brahmer J, Johnson DH, Laskin JL, Masters G, Milton D, et al: American society of clinical oncology clinical practice guideline update on chemotherapy for stage IV Non-small-cell lung cancer. J Clin Oncol 2009, 27:6251-6266.
4. Breathnach OS, Freidlin B, Conley B, Green MR, Johnson DH, Gandara DR, O'Connell M, Shepherd FA, Johnson BE: Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results. J Clin Oncol 2001, 19:1734-1742.
5. Suzuki K, Kodama S, Watanabe M: Role of Ku80-dependent end-joining in delayed genomic instability in mammalian cells surviving ionizing radiation. Mutat Res 2010, 683:29-34.
6. Postow L, Ghenoiu C, Woo EM, Krutchinsky AN, Chait BT, Funabiki H: Ku80 removal from DNA through double strand break-induced ubiquitylation. J Cell Biol 2008, 182:467-479.
7. Wang HC, Liu CS, Chiu CF, Chiang SY, Wang CH, Wang RF, Lin CC, Tsai RY, Bau DT: Significant association of DNA repair gene Ku80 genotypes with breast cancer susceptibility in Taiwan. Anticancer Res 2009, 29:5251-5254.
8. Xing J, Wu X, Vaporciyan AA, Spitz MR, Gu J: Prognostic significance of ataxia-telangiectasia mutated, DNA-dependent protein kinase catalytic subunit, and Ku heterodimeric regulatory complex 86-kD subunit expression in patients with nonsmall cell lung cancer. Cancer 2008, 112:2756-2764.
9. Pucci S, Mazzarelli P, Rabitti C, Giai M, Gallucci M, Flammia G, Alcini A, Altomare V, Fazio VM: Tumor specific modulation of KU70/80 DNA binding activity in breast and bladder human tumor biopsies. Oncogene 2001, 20:739-747.
10. Ye J, Ren ZY, Gu Q, Wang LM, Wang JL: Ku80 is differentially expressed in human lung carcinomas and upregulated in response to irradiation in mice. DNA Cell Biol 2011, 30:987-994.
11. Frit P, Canitrot Y, Muller C, Foray N, Calsou P, Marangoni E, Bourhis J, Salles B: Cross-resistance to ionizing radiation in a murine leukemic cell line resistant to cis-dichlorodiammineplatinum(II): role of Ku autoantigen. Mol Pharmacol 1999, 56:141-146.
12. Marme F, Hielscher T, Hug S, Bondong S, Zeillinger R, Castillo-Tong DC, Sehouli J, Braicu I, Vergote I, Isabella C, et al: Fibroblast growth factor receptor 4 gene (FGFR4) 388Arg allele predicts prolonged survival and platinum sensitivity in advanced ovarian cancer. Int J Cancer J int cancer 2012, 131:E586-591.
13. Muller C, Calsou P, Frit P, Cayrol C, Carter T, Salles B: UV sensitivity and impaired nucleotide excision repair in DNA-dependent protein kinase mutant cells. Nucleic Acids Res 1998, 26:1382-1389.
14. Teng XD: World Health Organization classification of tumours, pathology and genetics of tumours of the lung. Zhonghua bing li xue za zhi Chinese journal of pathology 2005, 34:544-546.
15. Wrona A, Jassem J: The new TNM classification in lung cancer. Pneumonol Alergol Pol 2010, 78:407-417.
16. Wang D, Xiang DB, Yang XQ, Chen LS, Li MX, Zhong ZY, Zhang YS: APE1 overexpression is associated with cisplatin resistance in non-small cell lung cancer and targeted inhibition of APE1 enhances the activity of cisplatin in A549 cells. Lung Cancer 2009, 66:298-304.
17. Li P, Wang K, Zhang J, Zhao L, Liang H, Shao C, Sutherland LC: The 3p21.3 tumor suppressor RBM5 resensitizes cisplatin-resistant human non-small cell lung cancer cells to cisplatin. Cancer Epidemiol 2012, 36:481-489.
18. Munakata Y, Saito-Ito T, Kumura-Ishii K, Huang J, Kodera T, Ishii T, Hirabayashi Y, Koyanagi Y, Sasaki T: Ku80 autoantigen as a cellular coreceptor for human parvovirus B19 infection. Blood 2005, 106:3449-3456.
19. Chang IY, Youn CK, Kim HB, Kim MH, Cho HJ, Yoon Y, Lee YS, Chung MH, You HJ: Oncogenic H-Ras up-regulates expression of Ku80 to protect cells from gamma-ray irradiation in NIH3T3 cells. Cancer Res 2005, 65:6811-6819.
20. Liang H, Zhang J, Shao C, Zhao L, Xu W, Sutherland LC, Wang K: Differential expression of RBM5, EGFR and KRAS mRNA and protein in non-small cell lung cancer tissues. J Exp Clin Cancer Res 2012, 31:36.
21. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-216.
22. Kelland L: The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 2007, 7:573-584.
23. Stewart DJ: Mechanisms of resistance to cisplatin and carboplatin. Crit Rev Oncol Hematol 2007, 63:12-31.
24. Wynne P, Newton C, Ledermann J, Olaitan A, Mould TA, Hartley JA: Enhanced repair of DNA interstrand crosslinking in ovarian cancer cells from patients following treatment with platinum-based chemotherapy. Br J Cancer 2007, 97:927-933.
25. Gullo C, Au M, Feng G, Teoh G: The biology of Ku and its potential oncogenic role in cancer. Bba-Rev Cancer 2006, 1765:223-234.
26. Johnstone RW, Ruefli AA, Lowe SW: Apoptosis: a link between cancer genetics and chemotherapy. Cell 2002, 108:153-164.
27. Siddik ZH: Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003, 22:7265-7279.
28. Soldani C, Scovassi AI: Poly(ADP-ribose) polymerase-1 cleavage during apoptosis: an update. Apoptosis 2002, 7:321-328.
29. Li G, Nelsen C, Hendrickson EA: Ku86 is essential in human somatic cells. Proc Natl Acad Sci USA 2002, 99:832-837.